Phase I/II study of GS030 in patients with retinitis pigmentosa

Trial Profile

Phase I/II study of GS030 in patients with retinitis pigmentosa

Planning
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs GS 030 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jan 2017 According to GenSight Biologics media release, the company announced that the the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to GS030 for the treatment of retinitis pigmentosa.
    • 21 Sep 2016 New trial record
    • 01 Sep 2016 According to GenSight Biologics media release, this trial is expected to start in Q32017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top